calcitonin (salmon) 400units/2ml solution for injection vials
salmon) 400units/2ml solution for injection vials (a a h pharmaceuticals ltd - calcitonin (salmon) - solution for injection - 200unit/1ml
calcitonin (salmon) 100units/1ml solution for injection ampoules
salmon) 100units/1ml solution for injection ampoules (a a h pharmaceuticals ltd - calcitonin (salmon) - solution for injection - 100unit/1ml
miacalcin nasal spray 200 iu
novartis pharmaceuticals canada inc - calcitonin (salmon synthetic) - spray - 200unit - calcitonin (salmon synthetic) 200unit - parathyroid and antiparathyroid agents
calcimar solution
sanofi-aventis canada inc - calcitonin (salmon synthetic) - solution - 200unit - calcitonin (salmon synthetic) 200unit - parathyroid and antiparathyroid agents
miacalcic 100 iu/ml solution for injection and infusion
essential pharma ltd - calcitonin, salmon - solution for injection/infusion - 100 international unit(s)/millilitre - calcitonin preparations; calcitonin (salmon synthetic)
miacalcin- calcitonin salmon injection, solution
mylan institutional llc - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - miacalcin injection is indicated for the treatment of symptomatic paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). miacalcin injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or
miacalcin- calcitonin salmon injection, solution
mylan institutional llc - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - miacalcin injection is indicated for the treatment of symptomatic paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). miacalcin injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or
miacalcic
essential pharma ltd - calcitonin, salmon - solution for inj/inf - 50 iu/ml - calcitonin (salmon synthetic)
miacalcic ampoules solution for inj/inf 100iu/ml
essential pharma ltd 7 egham business village, crabtree road, egham, surrey, tw20 8rb , united kingdom - calcitonin, salmon - solution for injection - calcitonin, salmon 100 iu/ml - calcium homeostasis
miacalcic 100 iu/ml solution for injection and infusion
essential pharma (m) limited - calcitonin - solution for injection/infusion - 100 international unit(s)/millilitre - calcitonin preparations; calcitonin (salmon synthetic)